Bevacizumab Local Complications

Ophthalmology

Volumn 116, Issue 11, 2009, Pages

  Gordon Angelozzi, Maximiliano ^a   Velez Montoya, Raul ^b   Fromow Guerra, Jans ^b   García Aguirre, Gerardo ^b   Guerrero Naranjo, Jose Luis ^b   Quiroz Mercado, Hugo ^a   Morales Cantón, Virgilio ^b  

^a Mexico Distrito Federal ^*

^b Mexico Distrito Federal   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ANTERIOR EYE CHAMBER INFLAMMATION; BURKHOLDERIA CEPACIA INFECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EYE INFLAMMATION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LETTER; MAJOR CLINICAL STUDY; MALE; OFF LABEL DRUG USE; PRIORITY JOURNAL; RETINA DETACHMENT; VISUAL ACUITY;

EID: 70350449697     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.07.027     Document Type: Letter

References (5)

1. Cohen M.H., Gootenberg J., Keegan P., and Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12 (2007) 713-718
2. Accessed on December (2007). http://www.fda.gov/medwatch/SAFETY/2005/Jan_PI/Avastin_PI.pdf
3. Kernt M., Neubauer A.S., and Kampik A. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 85 (2007) 119-120
4. Bakri S.J., Snyder M.R., Reid J.M., et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114 (2007) 855-859
5. Jager R.D., Aiello L.P., Patel S.C., and Cunningham Jr. E.T. Risks of intravitreous injection: a comprehensive review. Retina 24 (2004) 676-698